文献速递肝病消化道肿瘤与早癌

肝细胞癌从早期到晚期的基因组多样性临床影响

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.
PubMed 文献 · Hepatology · 2019-08-12

该研究分析了720例肝细胞癌患者的801个肿瘤样本(含410例切除、137例移植、122例经皮消融和52例非治愈性治疗),检测190个基因表达和31个基因突变,并对41例晚期和156例BCLC 0/A期全外显子测序。晚期HCC中SF3B1、TP53和RB1突变频率更高,G3转录组亚型富集且预后评分差,5基因评分可预测切除、消融及晚期HCC生存,22%晚期HCC携带潜在可靶向遗传变异。

要点

  • 晚期HCC中SF3B1(P=0.0003)、TP53(P=0.0006)和RB1(P=0.03)突变频率更高。
  • G1-G6转录组分类和5基因预后评分随疾病分期和治疗类型呈现不同分布。
  • 5基因评分可预测切除(P<0.0001)、消融(P=0.01)及晚期HCC(P=0.04)的生存。

核心结论

  • 跨不同分期的基因组分析揭示了肿瘤进展机制,并有助于识别靶向治疗应答的生物标志物。

研究设计与样本

  • 分析720例患者共801个HCC样本(410例切除、137例移植、122例经皮消融、52例非治愈性治疗)的190个基因表达和31个基因突变。
  • 对41例晚期HCC和156例BCLC 0/A期全外显子进行全外显子测序。
  • 队列BCLC分期分布:0期9.4%、A期59.5%、B期16.2%、C期14.9%。

主要发现

  • 801个HCC中最常见突变基因为TERT(58.1%)、CTNNB1(30.7%)、TP53(18.7%)、ARID1A(13%)、白蛋白(11.4%)、APOB(9.4%)和AXIN1(9.2%)。
  • 晚期HCC(BCLC B/C)中SF3B1(P=0.0003)、TP53(P=0.0006)和RB1(P=0.03)突变频率更高。
  • 晚期HCC在转录组水平显示G3富集(P<0.0001)、不良预后评分富集(P<0.0001)及增殖和去分化增加。
  • 5基因评分可预测切除治疗(P<0.0001)、消融治疗(P=0.01)和晚期HCC(P=0.04)患者的生存。
  • 22%的晚期HCC携带潜在可靶向遗传变异,MET扩增与接受特定MET抑制剂治疗的晚期HCC患者完全肿瘤缓解相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To date, genomic analyses of hepatocellular carcinoma (HCC) have been limited to early stages obtained from liver resection. We aim to describe the genomic profiling of HCC from early to advanced stages. We analyzed 801 HCC from 720 patients (410 resections, 137 transplantations, 122 percutaneous ablations, and 52 noncurative) for 190 gene expressions and for 31 gene mutations. Forty-one advanced HCC and 156 whole exome of Barcelona Clinic Liver Cancer (BCLC) 0/A were analyzed by whole-exome sequencing. Genomic profiling was correlated with tumor stages, clinical features, and survival. Our cohort included patients classified in BCLC stage 0 (9.4%), A (59.5%), B (16.2%), and C (14.9%). Among the overall 801 HCC, the most frequently mutated genes were telomerase reverse transcriptase (TERT) (58.1%), catenin beta 1 (CTNNB1) (30.7%), tumor protein 53 (TP53; 18.7%), AT-rich interaction domain 1A (ARID1A) (13%), albumin (11.4%), apolipoprotein B (APOB) (9.4%), and AXIN1 (9.2%). Advanced-stage HCC (BCLC B/C) showed higher frequencies of splicing factor 3b subunit 1 (SF3B1) (P = 0.0003), TP53 (P = 0.0006), and RB Transcriptional Corepressor 1 mutations (P = 0.03). G1-G6 transcriptomic classification and the molecular prognostic 5-gene score showed different distributions according to the stage of the disease and the type of treatment with an enrichment of G3 (P < 0.0001), poor prognostic score (P < 0.0001), and increased proliferation and dedifferentiation at the transcriptomic level in advanced HCC. The 5-gene score predicted survival in patients treated by resection (P < 0.0001) and ablation (P = 0.01) and in advanced HCC (P = 0.04). Twenty-two percent of advanced HCC harbored potentially druggable genetic alterations, and MET amplification was associated with complete tumor response in patients with advanced HCC treated by a specific MET inhibitor. Conclusion: Genomic analysis across the different stages of HCC revealed the mechanisms of tumor progression and helped to identify biomarkers of response to targeted therapies.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Nault JC, Martin Y, Caruso S, et al. Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. Hepatology. 2019. PMID: 31206197. doi:10.1002/hep.30811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。